Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Les services de santé américains limiteraient l’accès aux anticorps monoclonaux, un traitement efficace contre le Covid

Article original datant du 13/09/21«  Un législateur républicain exige de savoir pourquoi l’administration Biden semble limiter la capacité des médecins à commander des médicaments de traitement précoce pour les patients atteints du COVID-19. Le représentant Chip Roy (Républicain-Texas) a envoyé lundi une lettre au secrétaire du département de la santé et des services sociaux, Xavier […]

Selon le magasine NATURE : Si vous avez eu le COVID, vous produirez probablement des anticorps toute votre vie

Article original datant du 27/05/21 Les personnes qui se remettent d’un COVID-19 léger ont des cellules de moelle osseuse qui peuvent produire des anticorps pendant des décennies, bien que des variantes virales puissent atténuer la protection qu’ils offrent. De nombreuses personnes qui ont été infectées par le SRAS-CoV-2 produiront probablement des anticorps contre le virus […]